Rohlffs Fiona, Nana Petroula, Panuccio Giuseppe, Torrealba Jose I, Tsilimparis Nikolaos, Rybczynski Meike, Detter Christian, Kölbel Tilo
Department of Vascular Medicine, German Aortic Center, University Heart and Vascular Center UKE Hamburg, Hamburg, Germany.
Department of Vascular Surgery, Ludwig-Maximillian University Hospital, Munich, Germany.
Ann Surg. 2025 Jul 1;282(1):146-153. doi: 10.1097/SLA.0000000000006271. Epub 2024 Mar 19.
This study aimed to present the early and mid-term outcomes of fenestrated/branched thoracic endovascular aortic repair (f/bTEVAR) for aortic arch pathologies.
f/bTEVAR represents a less invasive treatment option for aortic arch diseases. Previous published series showed decreased early mortality and morbidity compared with open repair.
A single-center retrospective analysis of consecutive patients managed with f/bTEVAR (Cook Medical, Bloomington, IN) between September 1, 2011, and June 30, 2022, was conducted. Primary outcomes were technical success, 30-day mortality, and stroke. Data during follow-up and factors affecting early mortality and stroke were analyzed.
A total of 209 patients were included (38.3% females; mean age 69.8±3.4 years; mean aortic diameter 61±4.7 mm); 14.4% were managed urgently. Fenestrations/scallop configuration was used in 39.7%, branched devices in 55.5%, and branch/scallop combination in 4.8%. Landing to zone 0 was performed at 65.5% and in zone 1 at 32.1%. Non-native aortas were used for landing in 39.7%. Technical success was 97.1%, and 30-day mortality was 9.5%. Strokes were identified in 10%, and 5.7% major. Non-native proximal aortic landing zone was an independent protective factor for stroke ( P =0.002). Postoperative stroke ( P <0.001) and pericardial effusion ( P <0.001) were independently related to 30-day mortality. The mean follow-up was 21±8 months. The estimated survival and freedom from reintervention rates were 79.5% (SE: 3.1%) and 47.1% (SE: 4.3%) at 24 months, respectively.
f/bTEVAR presented high technical success and acceptable 30-day mortality. Non-native proximal landing zone was related to lower stroke rate. Half of the patients needed a reintervention within the 24-month follow-up.
本研究旨在呈现开窗/分支型胸主动脉腔内修复术(f/bTEVAR)治疗主动脉弓病变的早期和中期结果。
f/bTEVAR是主动脉弓疾病的一种侵入性较小的治疗选择。先前发表的系列研究表明,与开放修复相比,其早期死亡率和发病率有所降低。
对2011年9月1日至2022年6月30日期间接受f/bTEVAR(库克医疗公司,印第安纳州布卢明顿)治疗的连续患者进行单中心回顾性分析。主要结局指标为技术成功率、30天死亡率和卒中发生率。分析随访期间的数据以及影响早期死亡率和卒中的因素。
共纳入209例患者(女性占38.3%;平均年龄69.8±3.4岁;平均主动脉直径61±4.7mm);14.4%为急诊治疗。39.7%采用开窗/扇贝形结构,55.5%采用分支型装置,4.8%采用分支/扇贝形组合。65.5%的病例锚定在0区,32.1%在1区。39.7%使用非自体主动脉进行锚定。技术成功率为97.1%,30天死亡率为9.5%。卒中发生率为10%,其中5.7%为严重卒中。非自体近端主动脉锚定区是卒中的独立保护因素(P =0.002)。术后卒中(P <0.001)和心包积液(P <0.001)与30天死亡率独立相关。平均随访时间为21±8个月。24个月时的估计生存率和免于再次干预率分别为79.5%(标准误:3.1%)和47.1%(标准误:4.3%)。
f/bTEVAR技术成功率高,30天死亡率可接受。非自体近端锚定区与较低的卒中发生率相关。一半的患者在24个月随访期内需要再次干预。